TNF and inflammatory bowel disease: In inflammatory bowel disease (IBD), a chronic autoimmune group of disorders characterized by severe inflammation of different layers of the gastrointestinal tract, the introduction of MAbs targeting TNF-α was a game changer that significantly improved the quality of life for patients, delaying the onset of abdominal surgeries.